Bristol Myers Squibb

Health Care Pharmaceuticals New York City, New York Last filing Feb 11, 2026 · FY2025

                    Revenue
                    FY2025
                
$48.2B
                    3y CAGR +1.4%
                    
                    P25
                    
                    n/a
                    
                    Net income
                    FY2025
                
$7.1B
                    Net margin +14.6%
                    
                    P63
                    
                    n/a
                    
                    Total assets
                    FY2025
                
$90.0B
                    ROA +7.8%
                    
                    P65
                    
                    n/a
                    
                    Operating cash flow
                    FY2025
                
$14.2B
                    FCF margin +26.7%
                    
                    P94
                    
                    n/a

19 yrs · FY2007–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s revenue.

Balance Sheet

Assets, liabilities, and equity

35 accounts · 1 year

Total assets $90.0B

Total liabilities $71.5B

Shareholders equity $18.5B

Account	2025	Trend
Assets
Cash and Cash Equivalents	21.2%
Short Term Investments	1.0%
Accounts Receivable	19.9%
Inventory	5.6%
Prepaid Expenses	9.6%
Other Current Assets	9.6%
Total Current Assets	61.0%
Property,Plant and Equipment	15.7%
Operating Lease Assets	3.3%
Goodwill	45.1%
Intangible Assets	39.6%
Long Term Investments	1.5%
Deferred Tax Assets	11.2%
Other Noncurrent Assets	13.4%
Total Assets	186.8%
Liabilities
Accounts Payable	7.4%
Accrued Liabilities	4.7%
Current Portion of Long Term Debt	4.1%
Operating Lease Liabilities	0.4%
Other Current Liabilities	36.5%
Total Current Liabilities	48.6%
Long Term Debt	88.9%
Operating Lease Liabilities Noncurrent	3.8%
Deferred Tax Liabilities	0.5%
Other Noncurrent Liabilities	10.5%
Total Liabilities	148.4%
Equity
Preferred Stock	0.0%
Common Stock	0.6%
Additional Paid In Capital	96.3%
Retained Earnings	35.1%
Treasury Stock	90.4%
Accumulated Other Comprehensive Income	-3.2%
Noncontrolling Interest	0.1%
Total Stockholders Equity	38.3%
Total Liabilitiesand Equity	186.8%

Income Statement

Revenue, expense, and profitability

20 accounts · 1 year

Revenue $48.2B

Operating income $7.1B

Net income $7.1B

Account	2025	Trend
IncomeStatement
Revenues Total Revenue	100.0%
Expenses Cost of Revenue	28.9%
Expenses Research and Development	20.6%
Expenses Selling,General and Administrative	15.1%
Expenses Depreciation and Amortization	8.3%
Expenses Share Based Compensation	1.1%
Expenses Restructuring and Asset Impairment	1.2%
Expenses Operating Expenses	80.6%
Other Income Expense Operating Income	14.6%
Other Income Expense Interest Income	1.2%
Other Income Expense Interest Expense	3.9%
Other Income Expense Other Income/expense	-1.4%
Other Income Expense Income Before Tax	19.4%
Income Tax Income Tax Expense	4.7%
net Income net Income	14.6%
net Income Comprehensive Income	14.0%
Earnings Per Share Basic Eps	0.0%
Earnings Per Share Diluted Eps	0.0%
Earnings Per Share Weighted Average Shares Basic	4.2%
Earnings Per Share Weighted Average Shares Diluted	4.2%

Cash Flow Statement

Operating, investing, and financing flows

20 accounts · 1 year

Operating cash flow $14.2B

Investing cash flow $-4.1B

Financing cash flow $-10.3B

Account	2025	Trend
CashFlow
Operating Activities net Income	14.6%
Operating Activities Depreciation and Amortization	8.3%
Operating Activities Stock Based Compensation	1.1%
Operating Activities Deferred Income Taxes	-2.0%
Operating Activities Changes In Operating Assets and Liabilities	0.4%
Operating Activities net Cash From Operating Activities	29.4%
Investing Activities Capital Expenditures	2.7%
Investing Activities Business Acquisitions	8.2%
Investing Activities Purchases of Investments	4.1%
Investing Activities net Cash From Investing Activities	-8.6%
Financing Activities Proceeds From Debt	11.9%
Financing Activities Repayment of Debt	22.7%
Financing Activities Repurchase of Common Stock	0.0%
Financing Activities Dividends Paid	10.5%
Financing Activities Other Financing Activities	1.2%
Financing Activities net Cash From Financing Activities	-21.5%
Cash Reconciliation Effect of Exchange Rate On Cash	0.4%
Cash Reconciliation net Change In Cash	-0.3%
Cash Reconciliation Cash At Beginning of Period	21.2%
Cash Reconciliation Cash At End of Period	21.2%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 1 year

Ratio	2025
Profitability
Gross margin	+71.1%
Operating margin	+14.6%
Net margin	+14.6%
FCF margin	+26.7%
Growth
Revenue CAGR (3y)	+1.4%
Returns
ROE	+38.2%
ROA	+7.8%
ROIC	+10.1%
Liquidity
Current ratio	1.26x
Quick ratio	0.85x
Leverage
D/E	3.87x
Interest coverage	3.73x
Efficiency
Asset turnover	0.54x
Cash conversion cycle	+49d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Bristol Myers Squibb

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history